Add a listing
    Add a listing

    Celeris Therapeutics

      AI/ML discovery of protein degrading drugs.

    General
    • Headquarters

      Austria

    • Founders & Team

      Jakob Hohenberger, Christopher Trummer

    • Year Founded

      2020

    • Company type

      Private company

    • Funding stage

      Seed

    • Investors

      Longevitytech.fund, R42

    Technical Details
    • Aging Target

      Loss of proteostasis

    • Product modality

      proteins, small molecule drugs

    About

    Celeris Therapeutics is a deep learning company that uses innovative methods to degrade undruggable targets. We predict biomolecular interactions and generate small, organic molecules and degraders such as PROTACs against these targets. Celeris Therapeutics' technical solution is the web application Celeris One. Users of the platform are pharmaceutical and biotech companies with a focus on Targeted Protein Degradation. It consists of three modules: Xanthos, Hephaistos and Hades. A team of world-class experts, strong IP, and a global network facilitate the process of treating currently incurable diseases.

    How much is an extra decade of life worth to you? Make a bet on longevity science today.

    Donate to Impetus Grants

    You May Also Be Interested In